Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001144204-10-035731
Filing Date
2010-06-30
Accepted
2010-06-29 17:32:19
Documents
7
Period of Report
2010-03-31

Document Format Files

Seq Description Document Type Size
1 v189393_10-k.htm 10-K 1344637
2 GRAPHIC chart.jpg GRAPHIC 19532
3 v189393_ex23-1.htm EX-23.1 3121
4 v189393_ex31-1.htm EX-31.1 11270
5 v189393_ex31-2.htm EX-31.2 11423
6 v189393_ex32-1.htm EX-32.1 5611
7 v189393_ex32-2.htm EX-32.2 5644
  Complete submission text file 0001144204-10-035731.txt   1410367
Mailing Address 125 MAIDEN LANE, SUITE 309 NEW YORK NY 10038
Business Address 125 MAIDEN LANE, SUITE 309 NEW YORK NY 10038 212-797-9877
Tongli Pharmaceuticals (USA), Inc. (Filer) CIK: 0001052284 (see all company filings)

EIN.: 841090791 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-52954 | Film No.: 10924913
SIC: 7389 Services-Business Services, NEC